NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 14 July 2021

**Location:** via Zoom Teleconference

## Attendees

Committee members present

1. Professor Gary McVeigh (Chair) Present for all Items
2. Dr Lindsay Smith (Vice Chair) Present for all Items
3. Martin Bradley Present for all Items
4. Dr Matthew Bradley Items 5 to 6.2.2
5. Professor Sofia Dias Items 1 to 4.2.2 & 6 to 6.2.2
6. Professor Rachel Elliott Present for all Items
7. Professor Paula Ghaneh Present for all Items
8. Rebecca Harmston Present for all Items
9. Chris Herring Items 1 to 4.1.3 & 5 to 6.2.2
10. Dr Andrew Hitchings Present for all Items
11. Dr Robert Hodgson Present for all Items
12. Dr Bernard Khoo Items 4.1.3 to 6.2.2
13. Dr Ivan Koychev Present for all Items
14. Dr Soo Fon Lim Present for all Items
15. Dr Guy Makin Present for all Items
16. Giles Monnickendam Present for all Items
17. Malcolm Oswald Present for all Items
18. Dr Rebecca Payne Present for all Items
19. Professor John Watkins Present for all Items

NICE staff present

Helen Knight, Programme Director Items 5 to 5.2.2

Ross Dent, Associate Director Items 1 to 4.2.2

Linda Landells, Associate Director Items 5 to 6.2.2

Louise Jafferally, Project Manager Items 1 to 4.2.2

Kate Moore, Project Manager Items 4 to 4.1.3 & 5 to 6.2.2

Caron Jones, Health Technology Assessment Adviser Items 1 to 4.2.2

Hannah Nicholas, Health Technology Assessment Adviser Items 5 to 5.2.2

Victoria Kelly, Health Technology Assessment Adviser Items 6 to 6.2.2

Laura Coote, Health Technology Assessment Analyst (YHEC) Items 1 to 4.2.2

Sam Harper, Health Technology Assessment Analyst (YHEC) Items 1 to 4.2.2

Amy Crossley, Health Technology Assessment Analyst Items 5 to 5.2.2

Anita Sangha, Health Technology Assessment Analyst Items 6 to 6.2.2

Claire Hawksworth, Technical Analyst, Evidence Generation Items 1 to 4.2.2

Emily Eaton Turner, Technical Adviser, Commercial Risk Assessment Items 5 to 5.2.2

Thomas Strong, Technical Adviser, Commercial Risk Assessment Items 6 to 6.2.2

Maroulla Whiteley, Business Analyst, RIA Items 1 to 6.1.3

Hayley Garnett, Senior Medical Editor Items 1 to 4.2.2

Helen Barnett, Senior Medical Editor Items 5 to 5.2.2

Emilene Coventry, Senior Medical Editor Items 6 to 6.2.2

Erica Lamb, Media Relations Executive, Press Items 5 to 6.2.2

Mandy Tonkinson, Public Involvement Adviser, PIP Items 1 to 4.1.3, 5 to 5.1.3 & 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for all Items

Lucinda Evans, Coordinator, MIP Items 1 to 4.1.3, 5 to 5.1.3 & 6 to 6.1.3

Rosalee Mason, Coordinator, MIP Items 1 to 4.1.3

Iain Cannell, Administrator, TA Items 1 to 4.2.2

Celia Mayers, Administrator, TA Items 5 to 6.2.2

Sophie McHugh, Administrator, COT Items 1 to 4.2.2

Pratit Shah, Administrator Items 6 to 6.2.2

External review group representatives present

Katy Cooper, School of Health and Related Research (ScHARR), Items 1 to 4.1.3

Paul Tappenden, School of Health and Related Research (ScHARR), Items 1 to 4.1.3

Mark Corbett, Centre for reviews and Dissemination and Centre for Health Economics – York, Items 5 to 5.1.3

Matthew Walton, Centre for reviews and Dissemination and Centre for Health Economics – York, Items 5 to 5.1.3

Hannah Penton, Kleijnen Reviews Ltd Items 6 to 6.1.3

Robert Wolff, Kleijnen Reviews Ltd Items 6 to 6.1.3

Clinical and patient experts present

Professor Peter Clark, National Clinical lead for Cancer drugs, NHS England, Items 1 to 4.2.2

Jenny Abbott, Patient expert nominated by EGFR Positive UK, Items 1 to 4.1.3

Gary Doherty, Consultant Medical Oncologist, Clinical expert nominated by AstraZeneca, Items 1 to 4.1.3

Dr Eric Lim, Professor of Thoracic Surgery, Clinical expert nominated by AstraZeneca, Items 1 to 4.1.3

Dr Andrew Robinson, Consultant Pathologist, Clinical expert nominated by The Royal College of Pathologists, Items 1 to 4.1.3

Angela Terry, Patient expert nominated by EGFR Positive UK, Items 1 to 4.1.3

Dr Emma Drasar, Consultant Haematologist, Clinical expert nominated by UK Thalassaemia Society, Items 5 to 5.1.3

Sharon Hodgson, NHS Commissioning expert, NHS England, Items 5 to 5.1.3

Roanna Maharaj, Patient expert nominated UK Thalassaemia Society, Items 5 to 5.1.3

Dr Kate Ryan, Consultant Haematologist, Clinical expert nominated by Bluebird bio, Items 5 to 5.1.3

Gabriel Theophanous, Patient expert nominated by UK Thalassaemia Society, Items 5 to 5.1.3

Kye Gbangbola, Patient expert nominated by Sickle Cell Society, Items 6 to 6.1.3

June Okochi, Patient expert nominated by Sickle Cell Society, Items 6 to 6.1.3

Dr Paul Telfer, Senior Lecturer in Haematology, Clinical expert nominated by Novartis, Items 6 to 6.1.3

Observer present

Dr Megan John, TA Committee B General Practitioner Items 1 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Gary McVeigh welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 17 June 2021.

### Appraisal of osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (ID3835)

* 1. Part 1 – Open session
     1. The chair welcomed the invited clinical and patient experts, external review group representatives, the national clinical lead for Cancer drugs, members of the public and company representatives from AstraZeneca.
     2. The chair asked all committee members, clinical and patient experts, external review group representatives, the national clinical lead for Cancer drugs, and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Dr Ivan Koychev declared professional interests as he was recently awarded an NIHR fellowship which will be done in collaboration with AstraZeneca. The work will focus on non-oncological compounds for the treatment of Alzheimer's disease
* It was agreed that his declaration would not prevent Dr Koychev from participating in this section of the meeting.
* Nominated clinical expert Dr Gary Doherty declared financial interests as he has received speaker honoraria and consultancy fees from Amgen, AstraZeneca, Boehringer Ingelheim, Bayer, MSD, Novartis, Roche, Pfizer, and Merck.
* It was agreed that his declarations would not prevent Dr Doherty from providing expert advice to the committee.
* Nominated clinical expert Professor Eric Lim declared financial interests as he has received personal fees from AstraZeneca for advisory board, education meetings and grants and personal fees from Abbott Molecular, Glaxo Smith Kline, Pfizer, Norvatis, Medtronic / Covidien, Roche, Lily Oncology, Boehringer Ingelheim, Medela, ScreenCell, Johnson and Johnson / Ethicon, Clearbridge Biomedics, Illumina, Guardant Health, and BMS. he also has a patent P57988GB issued to Imperial Innovations relating to blood-based EGFR testing.
* It was agreed that his declarations would not prevent Professor Lim from providing expert advice to the committee.
* Nominated clinical expert Dr Andrew Robinson declared financial interests as he has received payment from Astra Zeneca for speaking engagement regarding impacts of COVID in histopathology in November 2020. Dr Robinson also declared that he is also due to receive honorarium for giving a presentation on June 30 2021.
* It was agreed that his declarations would not prevent Dr Robinson from providing expert advice to the committee.
* No further conflicts of interest were declared for this item.
  + 1. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Martin Bradley, Giles Monnickendam and Malcolm Oswald.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia (ID968)

* 1. Part 1 – Open session
     1. The chair Professor Gary McVeigh welcomed the invited clinical, patient and NHS commissioning experts, external review group representatives, members of the public and company representatives from Bluebird bio.
     2. The chair asked all committee members, clinical, patient and NHS commissioning experts, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Giles Monickendam declared indirect financial interests as his employer Vitaccess has conducted a digital registry study on burden of disease in transfusion dependent beta-thalassaemia for Bluebird Bio this was before Giles joined the company and was not involved.
* It was agreed that his declaration would not prevent Giles from participating in this section of the meeting.
* Nominated patient experts Roanna Maharaj and Gabriel Theophanous declared indirect interests as the UKTS received a grant for £15,000 on 17 January 2020 for the 2019 period, to contribute towards the production of the \ukts magazines and patient support meetings along with other pharma companies. On 29 April 2021 UKTS received the sum of £20,000.00 towards the patient conference, support, and production of magazines.
* It was agreed these declarations would not prevent Roanna and Gabriel from providing expert advice to the committee.
* Nominated clinical expert Dr Kate Ryan declared financial interests as she has received payment for advisory boards from Bluebird Bio in 2018 & 2019.
* It was agreed that her declaration would not prevent Dr Ryan from providing expert advice to the committee.
* No further conflicts of interest were declared for this item.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, clinical, patient and NHS commissioning experts, external review group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of crizanlizumab for preventing sickle cell crises in sickle cell disease (ID1406)

* 1. Part 1 – Open session
     1. The chair Professor Gary McVeigh welcomed the invited clinical, patient and NHS commissioning experts, external review group representatives, members of the public and company representatives from Novartis.
     2. The chair asked all committee members, invited clinical, patient and NHS commissioning experts, external review group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated patient expert Kye Gbangbola declared a financial interest as he has worked with Novartis when speaking at world sickle cell day spreading awareness of the condition.
* It was agreed that his declaration would not prevent Kye from providing expert advice to the committee.
* Nominated patient expert June Okochi declared financial interests as she has worked with Novartis as a patient advocate to raise awareness of sickle cell and is also a commissioner with the NHS.
* It was agreed that her declarations would not prevent June from providing expert advice to the committee.
* Nominated clinical expert Dr Paul Telfer declared financial interests as he has received research funding from Bluebird Bio and Global Blood Therapeutics, advisory board fees from Pfizer, Global Blood Therapeutics, Bluebird Bio, Novo Nordisk, Novartis and is a PI on clinical trials for CRISPR/VERTEX, Global Blood Therapeutics, Novartis.
* It was agreed that his declarations would not prevent Dr Telfer from providing expert advice to the committee.
* No further conflicts of interest were declared for this item.
  + 1. The chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, clinical, patient and NHS commissioning experts, external review group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 12 August 2021 and will start promptly at 9.30am.